Werner Milton H.
Known title: President and CEOCIK: 0001827621
Werner Milton H.'s purchase track record
How the stock did after each of Werner Milton H.'s open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
3
of 3 since November 17, 2021
Stock higher 6 months later
33%
3 months: 33%
Median 6-month return
-13.9%
3 months: -22.6%
Beat the S&P 500
33%
median -9.9% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/16/2022 | IKT | $4K | -22.6% | -13.9% | -3.9% |
| 5/20/2022 | IKT | $11K | +15.1% | +9.8% | +1.6% |
| 11/17/2021 | IKT | $47K | -36.9% | -66.2% | -16.3% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| IKT | ▲ Buy | Open Market | 5,000 | $4K | 8/16/2022 | View on chart |
| IKT | ▲ Buy | Open Market | 5,000 | $5K | 5/27/2022 | View on chart |
| IKT | ▲ Buy | Open Market | 10,000 | $6K | 5/20/2022 | View on chart |
| IKT | ▲ Buy | Option Exercise | 21,853 | $44K | 1/3/2022 | View on chart |
| IKT | ▲ Buy | Open Market | 3,186 | $6K | 11/17/2021 | View on chart |
| IKT | ▲ Buy | Open Market | 1,334 | $3K | 11/17/2021 | View on chart |
| IKT | ▲ Buy | Open Market | 1,100 | $2K | 11/17/2021 | View on chart |
| IKT | ▲ Buy | Open Market | 17,569 | $35K | 11/17/2021 | View on chart |
| IKT | ▲ Buy | Open Market | 400 | $772 | 11/17/2021 | View on chart |
| IKT | ▲ Buy | Option Exercise | 21,853 | $44K | 8/17/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 3, 2026
Inhibikase Announces Nasdaq Inducement Grants
Inhibikase Therapeutics disclosed that it granted inducement awards under Nasdaq Listing Rule 5635(c)(4). This type of grant is typically used to attract or retain new employees without requiring a shareholder vote. The company's stock is currently trading near its 52-week low, with an average analyst target of $6.00.
Inhibikase Announces Nasdaq Inducement Grants. Inhibikase Therapeutics disclosed that it granted inducement awards under Nasdaq Listing Rule 5635(c)(4). This type of grant is typically used to attract or retain new employees without requiring a shareholder vote. The company's stock is currently trading near its 52-week low, with an average analyst target of $6.00.